3Folkman J. What is the evidence that tumors are angiogenesis dependent.J Natl Cancer Inst,1990,82(1):4-6.
4Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL as first line therapy in subjects with metastatic CRC.Proc Am Soc Clin Oncol,2003,22:3646.
6Steward WP. Marimastat (BB2516): current status of development.Cancer Chemother Pharmacol, 1999, 43(Suppl):S56-S60.
7Steward WP, Thomas AL. Maristat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs, 2000,9:2913-2922.
8Vose JM, Link BK, Grossbard ML,et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hoddgkins lymphoma. J Clin Oncol, 2001,19:389-397.
9Coiffier B. Rituximab in the Treatment of Diffuse Large B-Cell Lymphoma. Semin Oncol, 2002,29(1 Suppl 2):S30-S35.
10Olayioye MA, Neve RM, Lane HA, et al. The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000,19:3159-3167.
5Dickman S.Antibodies stage a comeback in cancer treatment [J].Science,1998,280(5367):1196-1197.
6Weiner LM.An overview of monoclonal antibody therapy of cancer [J]. Semin Oncol,1999,26(4 Suppl 12):41-50.
7Bross PF,Beitz J,Chen G,et al.Approval summary:gemtuzumab ozogamicin in relapsed acute myeloid leukemia [J]. Clin Cancer Res,2001,7(6):1490-1496.
8Nguyen DT,Amess JA,Doughty H,et al.IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders:evaluation of response on 48 patients [J].Eur J Haematol,1999,62(2):76-82.
9Witzig TE,Gordon LI,Cabanillas F,et al.Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimrnunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade,follicular,or transformed B-cell non-Hodgkin's lymphoma [J].J Clin Oncol,2002,20(10):2453-2463.
10Ross JS,Fletcher JA.The HER-2/neu oncogene in breast cancer:prognostic factor,predictive factor,and target for therapy [J].Stem Cells,1998,16(6):413-428.
